BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seedor RS, Orloff M, Sato T. Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers (Basel) 2021;13:5503. [PMID: 34771666 DOI: 10.3390/cancers13215503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Marinkovic M, Pors LJ, van den Berg V, Peters FP, Schalenbourg A, Zografos L, Pica A, Hrbacek J, Van Duinen SG, Vu THK, Bleeker JC, Rasch CRN, Jager MJ, Luyten GPM, Horeweg N. Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy. Cancers 2021;13:6241. [DOI: 10.3390/cancers13246241] [Reference Citation Analysis]
2 Prasuhn M, Freitag JC, Lüken S, Kakkassery V, Merz H, Caliebe A, Spielmann M, Ranjbar M, Rommel F. Case Report: GNAQ- and SF3B1 Mutations in an Aggressive Case of Relapsing Uveal Ring Melanoma. Front Oncol 2022;12:873252. [PMID: 35692773 DOI: 10.3389/fonc.2022.873252] [Reference Citation Analysis]
3 Silva-rodríguez P, Fernández-díaz D, Bande M, Pardo M, Loidi L, Blanco-teijeiro MJ. GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. Cancers 2022;14:3066. [DOI: 10.3390/cancers14133066] [Reference Citation Analysis]
4 Blomen CL, Kött J, Hartung TI, Torster LK, Gebhardt C. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? Cancers (Basel) 2021;13:6390. [PMID: 34945010 DOI: 10.3390/cancers13246390] [Reference Citation Analysis]